Open Access

AMT: Preclinical pharmacology studies

  • Authors:
    • Faiz Niazi
    • Joachim Drevs
    • Klaus Diergarten
    • Annette Dorn
    • Armin Maier
    • Heinz Herbert Fiebig
    • Eddy Bruyns
    • Jürgen Scheele
  • View Affiliations

  • Published online on: May 1, 2009     https://doi.org/10.3892/ijo_00000261
  • Pages: 1341-1352
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Auron-Misheil-Therapy (AMT) consisting of aqueous camomile extract supplemented with calcium, vitamins, the antihistamine chlorpheniramine and human insulin is under development as anti-cancer treatment. AMT was preclinically investigated in tumour cell lines and tumour xenografts to guide clinical phase I/II studies. AMT was tested against 56 human tumour cell lines, in a clonogenic assay in 98 patient-derived xenografts and in in vivo studies. AMT showed in vitro cytotoxic activity with highest susceptibility in cervical cancer, glioblastoma and colon cancers. In the clonogenic assay, anti- cancer activity of AMT was most active in cervical and uterine tumours, in colon cancer, glioblastoma, leukaemia, melanoma and pancreatic cancer. In vivo, AMT showed slight activity in tumour xenograft models of colon and mammary cancer. It also showed immune stimulatory effects by induction of IL-6- and TNF-α secretion in human PBMCs. The immune stimulatory potential of AMT, together with slight anti-tumour efficacy observed in the present study, indicates a role of AMT in tumour therapy.

Related Articles

Journal Cover

May 2009
Volume 34 Issue 5

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Niazi F, Drevs J, Diergarten K, Dorn A, Maier A, Fiebig HH, Bruyns E and Scheele J: AMT: Preclinical pharmacology studies. Int J Oncol 34: 1341-1352, 2009.
APA
Niazi, F., Drevs, J., Diergarten, K., Dorn, A., Maier, A., Fiebig, H.H. ... Scheele, J. (2009). AMT: Preclinical pharmacology studies. International Journal of Oncology, 34, 1341-1352. https://doi.org/10.3892/ijo_00000261
MLA
Niazi, F., Drevs, J., Diergarten, K., Dorn, A., Maier, A., Fiebig, H. H., Bruyns, E., Scheele, J."AMT: Preclinical pharmacology studies". International Journal of Oncology 34.5 (2009): 1341-1352.
Chicago
Niazi, F., Drevs, J., Diergarten, K., Dorn, A., Maier, A., Fiebig, H. H., Bruyns, E., Scheele, J."AMT: Preclinical pharmacology studies". International Journal of Oncology 34, no. 5 (2009): 1341-1352. https://doi.org/10.3892/ijo_00000261